ClinicalTrials.Veeva

Menu

Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients

Viatris logo

Viatris

Status and phase

Completed
Phase 3

Conditions

Psychotic Disorders
Schizophrenia
Schizoaffective Disorder

Treatments

Drug: ziprasidone versus olanzapine , risperidone or quetiapine
Behavioral: Panss , CGI-C, UKU-SERS-Pa
Procedure: Blood tests

Study type

Interventional

Funder types

Industry

Identifiers

NCT00159770
A1281079

Details and patient eligibility

About

Evaluation of the antipsychotic efficacy and safety of ziprasidone versus olanzapine, risperidone or quetiapine in patients with schizophrenia, schizoaffective and schizophreniform disorders under naturalistic conditions of clinical practice

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Inpatients or outpatients with schizophrenia, schizoaffective and schizophreniform disorders (DSM-IV).
  • Patients without adequate current treatment (i.e. intolerance to their current treatment or lack of efficacy of current treatment) based on clinical judgement of the investigator

Exclusion criteria

  • A history of intolerance to ziprasidone, olanzapine, risperidone or quetiapine or any of its ingredients

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

43

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems